Effect of Quality Improvement Tools in Congestive Heart Failure (CHF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01446536
Recruitment Status : Completed
First Posted : October 5, 2011
Last Update Posted : March 20, 2012
Information provided by (Responsible Party):
Abhijeet Basoor, St. Joseph Mercy Oakland Hospital

Brief Summary:
Hypothesis: Quality Improvement tools like "Heart Failure Discharge Checklist" which emphasizes on proper education to patients, ensure appropriate dose titration and counselling improve outcome in congestive heart failure (CHF).

Condition or disease Intervention/treatment Phase
Congestive Heart Failure Other: Checklist cohort Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 96 participants
Masking: Single (Investigator)
Official Title: Decreased Readmissions and Improved Quality of Care With Use of Inexpensive Checklist in Heart Failure
Study Start Date : August 2008
Actual Primary Completion Date : June 2010
Actual Study Completion Date : June 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure
U.S. FDA Resources

Arm Intervention/treatment
No Intervention: Control group
This arm which was control group, was randomly selected among patients with acute decompensated heart failure in whom the checklist was not used. This group was managed as per the standard guidelines.
Active Comparator: Checklist (intervention) cohort
checklist was used in this group arbitrarily by their treating physician
Other: Checklist cohort
CHF discharge checklist was used arbitrarily by their treating physicians in addition to the standard therapy

Primary Outcome Measures :
  1. Readmissions [ Time Frame: 6 months ]
    Readmission to the hospital for CHF within 6 months of discharge

  2. Dose titration [ Time Frame: patients were followed during the time of hospital stay, average of 5 days ]
    up titration of medications including Beta blocer, ACE inhibitor or ARB was assessed during the hospital stay

Secondary Outcome Measures :
  1. Medications prescribed [ Time Frame: patients were followed during their hospital stay from admission to discharge, on an average of 5 days ]
    during the hospital stay and at discharge this outcome is measured/assessed

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients admitted to SJMO with principal diagnosis of acute decompensated heart failure

Exclusion Criteria:

  • Age less than 18 years
  • Pregnant women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01446536

United States, Michigan
St. Joseph Mercy Oakland Hospital
Pontiac, Michigan, United States, 48341
Sponsors and Collaborators
St. Joseph Mercy Oakland Hospital
Principal Investigator: Abhijeet Basoor, MD St. Joseph Mercy Oakland Hospital

Responsible Party: Abhijeet Basoor, Cardiology Fellow, St. Joseph Mercy Oakland Hospital Identifier: NCT01446536     History of Changes
Other Study ID Numbers: 11-09-02
First Posted: October 5, 2011    Key Record Dates
Last Update Posted: March 20, 2012
Last Verified: March 2012

Keywords provided by Abhijeet Basoor, St. Joseph Mercy Oakland Hospital:

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases